Angiogenesis inhibitor TNP-470 reduces human pancreatic cancer growth |
| |
Authors: | Hubert G Hotz MD Howard A Reber MD Birgit Hotz Premal C Sanghavi MD Tina Yu MD Thomas Foitzik MD Heinz J Buhr MD Oscar J Hines MD |
| |
Institution: | (1) Division of General Surgery, UCLA School of Medicine, 10833 LeConte Ave. 72-215 CHS, 90095-6904 Los Angeles, CA;(2) Benjamin Franklin Medical Center, Freie Universitaet, Berlin, Germany |
| |
Abstract: | In this study we investigated the effects of the angiogenesis inhibitor TNP-470 on human pancreatic cancer cells in vitro
and in vivo. The action of TNP-470 on vascular endothelial growth factor (VEGF) was also assessed. In vitro human pancreatic
cancer cells (MIAPaCa-2, AsPC-1, and Capan-1), and human umbilical vein endothelial cells (HUVEC) were exposed to increasing
concentrations (1 pg/ml to 100 (μg/ml) of TNP-470. Cell proliferation was assessed after 3 days by cell count and MTT assay.
In vivo, 5 Χ 106 pancreatic cancer cells were injected subcutaneously into nude mice. Four weeks later, 1 mm3 fragments of the resulting tumors were implanted into the pancreas of other mice. Animals received either TNP-470 (30 mg/kg
every other day) or vehicle subcutaneously for 14 weeks. The volume of the primary tumor and metastatic spread were determined
at autopsy. Concentrations of VEGF were determined in serum (VEGFS) and ascites (VEGFA) by enzyme-linked immunosorbent assay. Microvessel density was analyzed by immunohistochemistry in CD31 -stained tumor sections.
In vitro, proliferation and viability of the human pancreatic cancer cell lines were significantly inhibited at high concentrations
of TNP-470 (>1 μg/ml). In contrast, TNP-470 effectively decreased the growth of HUVEC at 100 pg/ml. In vivo, tumor volume
and dissemination scores were significantly lower in all three pancreatic cancer cell lines. VEGFS and VEGFA were not different between treated groups. Treatment with TNP-470 significantly reduced neoangiogenesis in tumors of all
three human pancreatic cancer cell lines: MIAPaCa-2 = 74.8 ±7.8/0.74 mm2 vs. 24.8 ±3.7/0.74 mm2; AsPC-1 = 65.3 ±5.0/0.74 mm2 vs. 26.0 ±3.4/0.74 mm2; and Capan-1 = 82.2 ±5.8/0.74 mm2 vs. 26.9 ±2.5/0.74 mm2 (P <0.001). However, survival was not statistically different between groups. TNP-470 reduced tumor growth and metastatic
spread of pancreatic cancer in vivo. This was probably due to the antiproliferative effect of the agent on endothelial cells
rather than to the direct inhibition of pancreatic cancer cell growth. TNP-470 activity was not associated with alteration
of VEGF secretion.
Supported by the R.S. Hirshberg Foundation and the Deutsche Forschungsgemeinschaft (grant HO 1843-1).
Presented at the Forty-First Annual Meeting of The Society for Surgery of the Alimentary Tract, San Diego, Calif., May 21–24,
2000. |
| |
Keywords: | Pancreatic cancer TNP-470 angiogenesis endothelial cell vascular endothelial growth factor |
本文献已被 ScienceDirect SpringerLink 等数据库收录! |
|